Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was downgraded by StockNews.com from a "hold" rating to a "sell" rating in a report released on Saturday.
Separately, HC Wainwright reissued a "neutral" rating on shares of Oramed Pharmaceuticals in a research note on Monday, September 9th.
Get Our Latest Research Report on ORMP
Oramed Pharmaceuticals Trading Up 1.2 %
Shares of ORMP stock traded up $0.03 during trading hours on Friday, reaching $2.44. The stock had a trading volume of 95,571 shares, compared to its average volume of 92,035. The stock's fifty day simple moving average is $2.38 and its 200 day simple moving average is $2.41. The firm has a market capitalization of $98.36 million, a PE ratio of 22.18 and a beta of 1.70. Oramed Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $3.67.
Hedge Funds Weigh In On Oramed Pharmaceuticals
A number of institutional investors have recently made changes to their positions in ORMP. Murchinson Ltd. increased its position in shares of Oramed Pharmaceuticals by 23.2% during the 2nd quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company's stock valued at $4,369,000 after purchasing an additional 320,495 shares during the last quarter. BML Capital Management LLC boosted its stake in Oramed Pharmaceuticals by 62.1% in the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company's stock worth $5,334,000 after buying an additional 837,153 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Oramed Pharmaceuticals during the third quarter valued at approximately $272,000. Dimensional Fund Advisors LP raised its stake in shares of Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company's stock worth $81,000 after acquiring an additional 10,774 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Oramed Pharmaceuticals in the 2nd quarter worth approximately $40,000. Institutional investors own 12.73% of the company's stock.
About Oramed Pharmaceuticals
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
See Also
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
